Answers are grounded in this paper and cite their sources.
Evaluates T-MSCs and BM-MSCs for alleviating aGvHD in humanized mice, suggesting potential clinical applications.
BACKGROUND: Despite being promising candidates for treating acute graft-versus-host disease (aGvHD), the efficacy and underlying mechanisms of mesenchymal stem cells (MSCs) may vary based on their sources. METHODS: T-MSCs, derived from trophoblast cells, and BM-MSCs, derived from bone marrow cells, were investigated for their efficacy in alleviating aGvHD in humanized NOD.Cg-Prkdcscid Il2rgtm1vst/Vst (NPG) mice. Clinical scoring and pathological damage were evaluated. Flow cytometry and cytometric bead array were used to assess T-cell proliferation and related cytokine release. Mechanisms involved in MSC-related efficacy were probed using different inhibitors and blocking antibodies. RESULTS: An acute, single dose of T-MSCs (3 × 105 cells/mouse) or BM-MSCs (3 × 105 cells/mouse) significantly ameliorated aGvHD severity, whereas delayed, multiple doses of either MSC type did not. At the cellular level, both T-MSCs and BM-MSCs inhibited the proliferation of CD4+ and CD8+ T cells and the upregulation of related cytokines, possibly involving prostaglandin E2 but not indoleamine 2,3-dioxygenase 1, transforming growth factor-β, or the programmed death-ligand 1 or Fas signaling. Additionally, the CD3+CD25high+Foxp3+ T cells were increased by both MSC types. CONCLUSIONS: Both T-MSCs and BM-MSCs can prevent CD4+ and CD8+ T-cell proliferation, possibly by facilitating prostaglandin E2 release and promoting the proliferation of CD3+CD25high+Foxp3+ T cells, thereby alleviating the development of aGvHD. T-MSCs and BM-MSCs may serve as promising candidates for treating aGvHD in the clinical setting.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: